BR112018069079A2 - construtos de alfavírus vivos atenuados e métodos e usos dos mesmos - Google Patents

construtos de alfavírus vivos atenuados e métodos e usos dos mesmos

Info

Publication number
BR112018069079A2
BR112018069079A2 BR112018069079A BR112018069079A BR112018069079A2 BR 112018069079 A2 BR112018069079 A2 BR 112018069079A2 BR 112018069079 A BR112018069079 A BR 112018069079A BR 112018069079 A BR112018069079 A BR 112018069079A BR 112018069079 A2 BR112018069079 A2 BR 112018069079A2
Authority
BR
Brazil
Prior art keywords
methods
alphavirus
live
attenuated
live attenuated
Prior art date
Application number
BR112018069079A
Other languages
English (en)
Portuguese (pt)
Inventor
Ann Livengood Jill
Duane Powell Timothy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of BR112018069079A2 publication Critical patent/BR112018069079A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112018069079A 2016-03-31 2017-03-28 construtos de alfavírus vivos atenuados e métodos e usos dos mesmos BR112018069079A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
BR112018069079A2 true BR112018069079A2 (pt) 2019-01-29

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069079A BR112018069079A2 (pt) 2016-03-31 2017-03-28 construtos de alfavírus vivos atenuados e métodos e usos dos mesmos

Country Status (17)

Country Link
US (1) US20190106682A1 (cg-RX-API-DMAC10.html)
EP (1) EP3436062A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019509750A (cg-RX-API-DMAC10.html)
KR (1) KR20180135913A (cg-RX-API-DMAC10.html)
CN (1) CN109195625A (cg-RX-API-DMAC10.html)
AU (1) AU2017241669A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018069079A2 (cg-RX-API-DMAC10.html)
CA (1) CA3019536A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018010359A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180457A (cg-RX-API-DMAC10.html)
DO (1) DOP2018000209A (cg-RX-API-DMAC10.html)
EC (1) ECSP18081582A (cg-RX-API-DMAC10.html)
MX (1) MX2018011839A (cg-RX-API-DMAC10.html)
PE (1) PE20190178A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018502120A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201808479VA (cg-RX-API-DMAC10.html)
WO (1) WO2017172698A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技(深圳)有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
JP5758632B2 (ja) 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用

Also Published As

Publication number Publication date
EP3436062A1 (en) 2019-02-06
MX2018011839A (es) 2019-05-23
PE20190178A1 (es) 2019-02-01
CR20180457A (es) 2019-04-09
US20190106682A1 (en) 2019-04-11
DOP2018000209A (es) 2019-01-31
JP2019509750A (ja) 2019-04-11
SG11201808479VA (en) 2018-10-30
PH12018502120A1 (en) 2019-07-15
KR20180135913A (ko) 2018-12-21
ECSP18081582A (es) 2019-02-28
CO2018010359A2 (es) 2018-12-14
WO2017172698A1 (en) 2017-10-05
CA3019536A1 (en) 2017-10-05
AU2017241669A1 (en) 2018-11-22
CN109195625A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
MX2018004916A (es) Vacuna contra el virus de la influenza de amplio espectro.
UY37563A (es) Aislados de bacillus y usos de los mismos
MX2015007755A (es) Vacunas contra virus de la influenza y sus usos.
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
MX2018000844A (es) Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera.
AR102657A1 (es) Composición para tratar telas
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
ZA202403393B (en) Synthetic chimeric poxviruses
MX2017005242A (es) Particulas tipo virus modificadas de cmv.
MX2018006386A (es) Produccion de virus en evos aviares.
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112015023332A2 (pt) Toxóide, composições e método relacionados
MX382530B (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
CU24283B1 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2663 DE 18-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.